<DOC>
	<DOCNO>NCT01177202</DOCNO>
	<brief_summary>The Purpose Of This Study Is To Assess The Safety , Immunogenicity , And Tolerability Of A H1N1 Vaccine In Healthy Adults</brief_summary>
	<brief_title>Study Safety Immunogenicity H1N1 Vaccine</brief_title>
	<detailed_description>This single center , placebo-controlled , single blind dose escalation study preliminarily assess safety , reactogenicity , immunogenicity different HAC1 vaccine formulation . This study ass novel HAC1 vaccine , plant derive . This vaccine compare Placebo normal ( 0.9 % ) saline , reference vaccine consist approve monovalent vaccine contain A/California ( H1N1 ) -like strain . Subjects receive 2 intramuscular injection experimental vaccine , placebo , reference vaccine Study Days 0 21</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Male female age 18 50 year inclusive Able give write informed consent participate Score least 80 % correct 10 question multiplechoice quiz ( 2 attempt ) Healthy , determine medical history , physical examination , weight , vital sign , clinical safety laboratory examination baseline Females must fulfill one follow criterion : At least one year postmenopausal ; Surgically sterile surgically sterile partner ; Willing abstain sexual intercourse ; Willing use reliable form contraception approve investigator ( e.g. , oral , implantable , transdermal injectable contraceptive , intrauterine device ( IUD ) , female condom , diaphragm spermicide , cervical cap , male condom ) 30 day prior first vaccination 3 month second vaccination Women childbearing potential must negative urine pregnancy test within 24 hour precede receipt dose Comprehension study requirement , express availability require study period , ability attend schedule visit contact telephone throughout followup period Prior receipt 20102011 seasonal influenza vaccine contain A/California/04/09like virus Screening H1N1 titer &gt; 1:40 Presence significant uncontrolled medical psychiatric illness ( acute chronic ) include institution new medical surgical treatment significant dose alteration uncontrolled symptom drug toxicity within 3 month screen Presence medical condition may associate impaired immune responsiveness , include diabetes mellitus Cancer , treatment cancer , within previous 3 year , exclude basal cell carcinoma squamous cell carcinoma Presently receive history receiving , precede 3month period , medication treatment may adversely affect immune system : This include allergy injection , immune globulin , interferon , immunomodulators , cytotoxic drug drug know frequently associate significant major organ toxicity , systemic corticosteroid ( oral injectable ) ; Inhaled topical corticosteroid allow Receipt blood blood product 8 week prior vaccination plan administration study period Donation blood blood product within 8 week prior vaccination time study Receipt plan administration nonstudy vaccine within 30 day prior vaccination ; Immunization emergency basis Tetanus Toxoids Adsorbed adult use ( Td Tdap ) vaccine 8 day least 8 day dose study vaccine allow History anaphylactic type reaction inject vaccine Receipt investigational product nonregistered drug within 30 day prior vaccination currently enrol investigational drug study intend enroll study within ensue study period History drug chemical abuse year study Positive serology HIV1 HIV2 , HBsAg HCV antibodies Unwilling allow storage specimen future use Acute disease within 72 hour prior vaccination : Acute disease define presence moderate severe illness ( determined Investigator medical history physical examination ) without fever ( &gt; 38ºC / &gt; 100.4ºF ) , oral temperature &gt; 38ºC orally ; Study vaccine administer person minor illness . Any condition , opinion investigator , might interfere interpretation data support primary study objective</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>HAC1 , H1N1</keyword>
</DOC>